IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2005 by Danish HIV Research Group.
Recruitment status was: Active, not recruiting
Recruitment status was: Active, not recruiting
Sponsor:
Danish HIV Research Group
Collaborators:
Rigshospitalet, Denmark
Hvidovre University Hospital
Odense University Hospital
Aarhus University Hospital
Aalborg Universitetshospital
Abbott
Information provided by:
Danish HIV Research Group
ClinicalTrials.gov Identifier:
NCT00135460
First received: August 25, 2005
Last updated: March 13, 2006
Last verified: September 2005
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including peripheral lipoatrophy.
There is limited knowledge about lipodystrophic adverse events in nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens. The hypothesis is that nucleoside analogues are responsible for development of lipoatrophy, and, patients receiving an NRTI-sparing regimen will have little risk of peripheral lipoatrophy.
The researchers plan to perform a randomized study recruiting 100 antiretroviral naive patients that will be randomized to receive a nucleoside analogue sparing HAART regimen or a protease-inhibitor sparing regimen.
The main endpoint is changes in peripheral fat mass as determined by dual energy X-ray absortiometry (DEXA)-scanning.
| Condition | Intervention | Phase |
|---|---|---|
| HIV-Associated Lipodystrophy Syndrome | Drug: nucleoside analogue sparing HAART regimen | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in Patients With HIV. Influence on Morphological and Metabolic Disorders. A Randomized, Open-Label Multicenter Trial. |
Resource links provided by NLM:
MedlinePlus related topics:
HIV/AIDS
Drug Information available for:
Proteinase inhibitor
U.S. FDA Resources
Further study details as provided by Danish HIV Research Group:
Primary Outcome Measures:
- Changes in peripheral fat mass, determined by DEXA-changes
- Changes in body composition from baseline, determined by patient and physician in a standardized questionnaire and by standardized clinical examination
- Change from baseline in fasting lipids and subsets hereof
- Development of impaired glucose tolerance and insulin resistance
Secondary Outcome Measures:
- Proportion of patients with HIV-RNA < 20 copies after 24, 48, 72 and 96 weeks
- Change in CD4 cell count from baseline after 24, 48, 72 and 96 weeks
- Incidence of adverse events
- Incidence of clinical disease progression
- Proportion of patients who have virological, immunological or clinical failure or treatment-limiting adverse events at week 24, 48 and 96
- Change in plasma lactate from baseline
- Time to discontinuation of the randomized therapy and reasons for this
- Incidence of genotypical and virological resistance
- Development of osteopenia, judged by DEXA-scan
- Compliance – proportion of patients who report to take 90%, respectively 95% of their medications at week 4, 48 and 96
| Estimated Enrollment: | 100 |
| Study Start Date: | June 2003 |
| Estimated Study Completion Date: | November 2007 |
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Antiretroviral naïve patients
- HIV-1 infection as documented by a licensed HIV-1 antibody ELISA.
- Fulfilling the criteria for starting antiretroviral therapy.
- Ability to understand and provide written informed consent.
Exclusion Criteria:
- Women being pregnant or breast-feeding.
- Fertile women using no safe contraception.
- Patients with active intravenous drug use.
- Abuse of alcohol, which in the opinion of the treating physician will reduce the patient´s ability to follow a therapeutic regimen and evaluations of the protocol.
- Ongoing medical treatment, which has a clinically significant interaction with lopinavir, ritonavir or efavirenz.
- Creatinine > 200 mmol/l.
- ALT or AST > 5 times upper normal value (200U/l).
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00135460
Please refer to this study by its ClinicalTrials.gov identifier: NCT00135460
Locations
| Denmark | |
| Department of Infectious Diseases, Hvidovre University Hospital | |
| Hvidovre, Copenhagen, Denmark, 2650 | |
| Department of Infectious Diseases, Aalborg Hospital | |
| Aalborg, Denmark | |
| Department of Infectious Diseases, Aarhus University Hospital | |
| Aarhus, Denmark, 8200 | |
| Department of Infectious Diseases, Rigshospitalet | |
| Copenhagen, Denmark, 2100 | |
| Department of Infectious Diseases, Odense University Hospital | |
| Odense, Denmark, 5000 | |
Sponsors and Collaborators
Danish HIV Research Group
Rigshospitalet, Denmark
Hvidovre University Hospital
Odense University Hospital
Aarhus University Hospital
Aalborg Universitetshospital
Abbott
Investigators
| Study Chair: | Jan Gerstoft, M.D., DMSc | Rigshospitalet, Denmark |
| Principal Investigator: | Niels Obel, M.D., DMSc | Odense University Hospital |
| Principal Investigator: | Court Pedersen, Professor | Odense University Hospital |
| Principal Investigator: | Lars Mathiesen, M.D.,DMSc | Hvidovre University Hospital |
| Principal Investigator: | Henrik Nielsen, M.D.,DMSc | Aalborg Universitetshospital |
| Principal Investigator: | Alex Laursen, M.D., DMSc | Aarhus University City |
| Principal Investigator: | Ann-Brit E Hansen, M.D. | Copenhagen University Hospital Rigshospitalet and Odense University Hospital |
More Information
| ClinicalTrials.gov Identifier: | NCT00135460 History of Changes |
| Other Study ID Numbers: |
2612-2198 |
| Study First Received: | August 25, 2005 |
| Last Updated: | March 13, 2006 |
Keywords provided by Danish HIV Research Group:
|
HIV Lipoatrophy Lipodystrophy |
Treatment Naive HIV Infections Hypercholesterolemia |
Additional relevant MeSH terms:
|
Lipodystrophy HIV-Associated Lipodystrophy Syndrome Skin Diseases, Metabolic Skin Diseases Lipid Metabolism Disorders Metabolic Diseases HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral |
Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Protease Inhibitors HIV Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on June 23, 2017